KMDA

Kamada Ltd. (NASDAQ:KMDA) is an Israeli biopharmaceutical company founded in 1990 and headquartered in Rehovot, Israel. The company went public on NASDAQ in 2013 and has transformed from a single-product dependency into a diversified plasma-derived therapeutics company. Kamada specializes in developing, manufacturing, and commercializing plasma-derived protein therapeutics, primarily targeting rare diseases and immune-related conditions. The company operates through two main business segments: Proprietary Products and Distribution, with a growing focus on the U.S. market which now represents approximately 60-70% of its revenues.